The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy.
about
Conformational transition pathway in the activation process of allosteric glucokinaseCrystal structure of E339K mutated human glucokinase reveals changes in the ATP binding siteA panel of diverse assays to interrogate the interaction between glucokinase and glucokinase regulatory protein, two vital proteins in human diseaseGlucokinase and glucokinase regulatory proteins are functionally coexpressed before birth in the rat brainLifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD.Lys169 of human glucokinase is a determinant for glucose phosphorylation: implication for the atomic mechanism of glucokinase catalysis.Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene.Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families.Reclassification of diabetes etiology in a family with multiple diabetes phenotypesGlucokinase activity in the arcuate nucleus regulates glucose intake.Phenotypic severity of homozygous GCK mutations causing neonatal or childhood-onset diabetes is primarily mediated through effects on protein stability.Biochemical basis of glucokinase activation and the regulation by glucokinase regulatory protein in naturally occurring mutations.Intragenic suppression of Gal3C interaction with Gal80 in the Saccharomyces cerevisiae GAL gene switchComprehensive in silico mutagenesis highlights functionally important residues in proteins.Discovery of a novel site regulating glucokinase activity following characterization of a new mutation causing hyperinsulinemic hypoglycemia in humansConformational transition pathway in the allosteric process of human glucokinase.Gene-altered mice and metabolic flux control.Repair of diverse diabetic defects of β-cells in man and mouse by pharmacological glucokinase activationHyperinsulinism in infancy: from basic science to clinical disease.GCK-MODY (MODY 2) Caused by a Novel p.Phe330Ser Mutation.Ketogenic diet in a patient with congenital hyperinsulinism: a novel approach to prevent brain damageFamilial adult onset hyperinsulinism due to an activating glucokinase mutation: implications for pharmacological glucokinase activation.Genetic polymorphism of glucokinase on the risk of type 2 diabetes and impaired glucose regulation: evidence based on 298,468 subjects.SUMOylation of pancreatic glucokinase regulates its cellular stability and activityThe molecular mechanisms, diagnosis and management of congenital hyperinsulinismGlucokinase activators in diabetes management.Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations.Latest research and development trends in non-insulin anti-diabetics.Molecular targeting of the GK-GKRP pathway in diabetes.Susceptibility of glucokinase-MODY mutants to inactivation by oxidative stress in pancreatic β-cells.Structure-function analysis of the alpha5 and the alpha13 helices of human glucokinase: description of two novel activating mutations.Lack of glibenclamide response in a case of permanent neonatal diabetes caused by incomplete inactivation of glucokinaseGlucokinase thermolability and hepatic regulatory protein binding are essential factors for predicting the blood glucose phenotype of missense mutations.Arcuate nucleus glucokinase and dietary glucose intake.Insights into the structure and regulation of glucokinase from a novel mutation (V62M), which causes maturity-onset diabetes of the young.Non-insulinoma persistent hyperinsulinaemic hypoglycaemia caused by an activating glucokinase mutation: hypoglycaemia unawareness and attacks.Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy.Heterogeneity in phenotype of hyperinsulinism caused by activating glucokinase mutations: a novel mutation and its functional characterization.Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes.Congenital hyperinsulinism: global and Japanese perspectives.
P2860
Q27316020-0B87B732-3EE1-4542-BCD1-7BF94CBCB305Q27667057-809C1EC2-E942-42A0-99F7-4BF8E4764326Q28539913-B597718C-F8C1-4172-8CEB-044024D2B87AQ28573569-6FFC9728-2428-4FD1-BA0B-8BD6C6685143Q30713822-680C6075-9FD8-4C5B-8F15-14E302D56D6FQ33484164-1C9EF19F-42A9-42CD-AB20-159BCAF4CDCDQ33642045-FA52215A-B5AD-48CF-8636-00C372161DE3Q34211860-48D715EE-12FE-4987-A069-D2E6F6246327Q34294841-42B4FFDC-DFDD-49F6-AA5E-0A87290DED55Q34452560-5B8929BE-E715-4A56-8735-96E3E2638E09Q34555428-C68A1956-FEE7-468E-BBE9-02E5AA2226F3Q34578853-EA0546AE-0EC9-48C6-B475-7889FEBD6764Q34587520-06A20A45-CC1B-436A-BE94-A0013D4F742BQ34806039-5F9EA52B-19DD-456A-AE83-170925E89D06Q34998302-7485AD13-5DEA-4B46-8856-624510648417Q35037241-CBE4E70D-F773-4237-BB2B-28E0D847D996Q35146393-31AECFF1-F6BA-4793-B277-A1363E818406Q35611074-2177C5CC-6CBF-4943-B052-48520D345593Q35625609-4FDAA654-9532-4AE4-9B1C-7A452C7743BCQ35687357-BDF8DAA9-3F4F-46F8-8105-02306F6F6204Q36087987-CCC4DC66-C5E9-424E-971A-D91AD0EF096AQ36528937-B7165464-B8DD-4CBB-B4B2-F91EA70756A2Q36618555-75A4259A-A14B-4953-964E-4FD42703206FQ36635942-5E3E0EA2-873C-4CA5-9215-DACB748E7A03Q36862232-93BCBB5B-D025-4B50-9C71-C265BD0AEA31Q37071183-BD38C896-4098-4FB2-9476-EE2E01610BEFQ37193748-E1AB51FF-6529-4B38-94F0-6F286481B90EQ38080471-A4014D2A-28D5-473D-B226-6239CAE4241DQ38260964-C2D86924-8905-4D42-8162-3BE3B5B6B69EQ39220924-DA5F934A-938B-478E-AB53-312BFA21A0B1Q41940930-2522898F-232F-4D7C-85A7-2E99B4321374Q41999924-1F9D72EA-B14D-4610-A0BC-8AD5732ECB75Q42165162-472313ED-A622-4042-8671-1EFF0C9BEA36Q43164260-5D0822F7-87EC-4663-8800-A7EF1FDE5858Q45242050-FF61556A-AF47-4B0F-B14E-F9CEDE395F7BQ46798932-E6CC8DFE-E6E2-4F9F-8875-18180AAEACDEQ46919848-E40D5012-101D-4E2F-8614-8A815495A810Q48181466-618DA89E-F37E-49BC-9B20-8EF5EFC6C101Q51107449-936AA3B1-78AF-46CA-B373-E9E81F45E7FEQ51261501-FA7F9560-B012-4FC7-B8FF-5DF213BB31DC
P2860
The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The second activating glucokin ...... eostasis and diabetes therapy.
@en
The second activating glucokinase mutation
@nl
type
label
The second activating glucokin ...... eostasis and diabetes therapy.
@en
The second activating glucokinase mutation
@nl
prefLabel
The second activating glucokin ...... eostasis and diabetes therapy.
@en
The second activating glucokinase mutation
@nl
P2093
P50
P1433
P1476
The second activating glucokin ...... eostasis and diabetes therapy.
@en
P2093
Antonio Cuesta-Munoz
Bendt B Jacobsen
Carol Buettger
Chiyo Shiota
Franz M Matschinsky
Mark A Magnuson
Ornella Massa
Stella Odili
Torben Hansen
P304
P356
10.2337/DIABETES.51.4.1240
P407
P577
2002-04-01T00:00:00Z